Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia

Research output: Contribution to journalArticle

Researchers

  • Martin Adiels
  • Marja Riitta Taskinen
  • Elias Björnson
  • Linda Andersson
  • Niina Matikainen
  • Sanni Söderlund
  • Juhani Kahri
  • Antti Hakkarainen

  • Nina Lundbom
  • Carina Sihlbom
  • Annika Thorsell
  • Haihong Zhou
  • Kirsi H. Pietiläinen
  • Chris Packard
  • Jan Borén

Research units

  • University of Gothenburg
  • University of Helsinki
  • Merck
  • University of Glasgow

Abstract

Aims: To investigate how apolipoprotein C-III (apoC-III) metabolism is altered in subjects with type 2 diabetes, whether the perturbed plasma triglyceride concentrations in this condition are determined primarily by the secretion rate or the removal rate of apoC-III, and whether improvement of glycaemic control using the glucagon-like peptide-1 analogue liraglutide for 16 weeks modifies apoC-III dynamics. Materials and Methods: Postprandial apoC-III kinetics were assessed after a bolus injection of [5,5,5- 2 H 3 ]leucine using ultrasensitive mass spectrometry techniques. We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects. Liver fat content, subcutaneous abdominal and intra-abdominal fat were determined using proton magnetic resonance spectroscopy. Results: Improved glycaemic control by liraglutide therapy for 16 weeks significantly reduced apoC-III secretion rate (561 ± 198 vs. 652 ± 196 mg/d, P = 0.03) and apoC-III levels (10.0 ± 3.8 vs. 11.7 ± 4.3 mg/dL, P = 0.035) in subjects with type 2 diabetes. Change in apoC-III secretion rate was significantly associated with the improvement in indices of glucose control (r = 0.67; P = 0.009) and change in triglyceride area under the curve (r = 0.59; P = 0.025). In line with this, the apoC-III secretion rate was higher in subjects with type 2 diabetes compared with BMI-matched non-diabetic subjects (676 ± 208 vs. 505 ± 174 mg/d, P = 0.042). Conclusions: The results reveal that the secretion rate of apoC-III is associated with elevation of triglyceride-rich lipoproteins in subjects with type 2 diabetes, potentially through the influence of glucose homeostasis on the production of apoC-III.

Details

Original languageEnglish
Pages (from-to)1861-1870
JournalDiabetes, Obesity and Metabolism
Volume21
Issue number8
Early online date1 Jan 2019
Publication statusPublished - Aug 2019
MoE publication typeA1 Journal article-refereed

    Research areas

  • apolipoprotein C-III, kinetics, lipoproteins, stable isotopes, type 2 diabetes

ID: 34206450